Tiziana Life Sciences (TLSA) CEO boosts stake with 163,400-share purchase

Rhea-AI Filing Summary

Tiziana Life Sciences LTD reported that its Chief Executive Officer, Ivor Elrifi, bought 163,400 shares of Tiziana common stock in the open market on December 15, 2025. These purchases increase his total open-market purchased holdings to 357,848 shares.

This move means the company’s top executive has committed more of his own capital to Tiziana’s stock, which some investors view as a sign of confidence in the business. The disclosure is provided in a Form 6-K, with an accompanying press release furnished as Exhibit 99.1.

Insights

Insider transactions and governance analyst

CEO Ivor Elrifi increased his personal stake with a 163,400-share open-market purchase.

Tiziana Life Sciences LTD disclosed that CEO Ivor Elrifi bought 163,400 shares of common stock in open-market transactions on December 15, 2025, bringing his total open-market purchased holdings to 357,848 shares. Open-market insider buying is discretionary and typically reflects the executive’s own assessment of the company’s prospects and valuation.

The filing does not quantify the purchase in currency or as a percentage of shares outstanding, so its financial magnitude for the company’s capital structure cannot be gauged from this excerpt alone. However, it does clarify that the information is being furnished, not filed, which limits how it is treated under certain U.S. securities law provisions.

Investors who follow insider activity may see this as a relevant data point about leadership alignment, while the actual impact on trading dynamics will depend on future company developments and additional disclosures in upcoming reports.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

December 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On December 15, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: December 15, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated December 15, 2025

3

FAQ

What did Tiziana Life Sciences (TLSA) disclose in this Form 6-K?

Tiziana Life Sciences LTD disclosed that its Chief Executive Officer, Ivor Elrifi, purchased 163,400 shares of the company’s common stock in open-market transactions, and that his total open-market purchased holdings now stand at 357,848 shares.

How many Tiziana Life Sciences shares did CEO Ivor Elrifi buy and where?

CEO Ivor Elrifi purchased 163,400 shares of Tiziana Life Sciences common stock in the open market, according to the Form 6-K disclosure.

What is Ivor Elrifi’s current total of purchased Tiziana Life Sciences shares?

After the most recent open-market purchase, Ivor Elrifi has a total of 357,848 Tiziana Life Sciences common shares that he has purchased.

When was the CEO’s share purchase and Form 6-K report dated for Tiziana Life Sciences?

The Form 6-K states that on December 15, 2025, Tiziana Life Sciences issued the report announcing CEO Ivor Elrifi’s open-market purchase of 163,400 shares of common stock.

How is the Tiziana Life Sciences press release related to this Form 6-K?

The report notes that the related Tiziana Life Sciences LTD press release is included as Exhibit 99.1 to the Form 6-K and that this information is being furnished rather than deemed filed under certain U.S. securities law provisions.